Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Esketamine, as a powerful analgesic intravenous anesthetic, has a rapid onset and elimination effect, does not inhibit spontaneous respiration, and can slightly stimulate the circulatory system. It has been confirmed that esketamine can effectively combat opioid related complications, especially life-threatening respiratory suppression. Thus becoming a new powerful perioperative analgesic drug. At the same time, esketamine has been licensed for the treatment of "resistant depression" and emergency treatment for patients in crisis states of depression. But the evidence for its safety and effectiveness is insufficient. We have designed a randomized controlled clinical trial to investigate the effect of an established general anesthesia strategy without opioids by using esketamine on postoperative depressive in obese patients undergoing laparoscopic sleeve gastrectomy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Second Hospital of Anhui Medical University
• Treatments: Esketamine

Criteria

Inclusion Criteria:

• BMI≥40kg/m2 or BMI>35 kg/m2 with an existing comorbidity

• scheduled for selective LSG

• American Society of Anesthesiologists physical status I-III

• HAMD>7

• with informed consent

Exclusion Criteria:

• Patients diagnosed with significant comorbidities, such as cardiopathy, chronic respiratory conditions, abnormal hepatic and/or renal function, coagulation dysfunction, major psychiatric or neurological disorders

• Patients allergy to esketamine or other drugs used in the study

• Patients are scheduled for/plan to have an additional surgery during the 3-month follow-up period

• Patients suffer from acute or chronic pain with analgesics, or take anticathartic, glucocorticoid medications

• Patients involved in another research study

• Patients will likely have problems, in the judgement of the investigator, with maintaining follow-up

• Any other reasons the investigator feels is relevant for excluding the patient

• lack of patient consent